Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

During Shanghai Visit PhRMA Chairman Calls For Regulatory Systems To Support Innovation

This article was originally published in The Pink Sheet Daily

Executive Summary

During a three-day visit in Shanghai, PhRMA Chairman Robert Hugin met local stakeholders and outlined the organization’s advocacy priorities in China amidst the evolving Drug Administration Law.

You may also be interested in...



NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research

With $230 million from industry and NIH, the Accelerating Medicines Partnership seeks to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.

Sanofi-Aventis Asia Pacific R&D Head Frank Jiang Sees Progress And Promise In Research Alliances Across China

BEIJING - As the Paris-headquartered Sanofi-Aventis expands its matrix of research alliances across China, this virtual R&D web is beginning to churn out tangible signs of progress and promise, according to a high-ranking Sanofi scientist based in China

CROs at risk from China's new inventor regulation?

China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel